Abstracts tagged "interferon"

Abstract Number: 1864 • ACR Convergence 2025
Mitochondrial Dysfunction Drives cGAS-STING–Mediated Type I Interferon Production and Fibrosis in Systemic Sclerosis
Giulio Forte¹, Vasiliki Liakouli¹, Alessia Salzillo², Mario Angeli³, Daniele Mauro¹, Antonio Ciancio¹, Barbara De Marino², Iacopo Panarese¹, Mario Faenza¹, roberto giacomelli⁴, Andreas Ramming⁵ and Francesco Ciccia⁶, ¹Università della Campania Luigi Vanvitelli, Naples, Italy, ²University of Campania L. Vanvitelli, Naples, Italy, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁴Università Campus Bio-Medico, Roma, Italy, ⁵Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by type I interferon (IFN-I) production and mitochondrial dysfunction. Emerging evidence suggests that activation of the…
Abstract Number: 1512 • ACR Convergence 2025
Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Takemichi Matsui¹, Yumi Tsuchida², Takahiro Itamiya², Mineto Ota², Toshihiko Komai², Haruka Tsuchiya², Hirofumi Shoda², Tomohisa Okamura² and Keishi Fujio², ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: With the introduction of anifrolumab to clinical practice, there is a growing interest in identifying factors associated with IFN activity in patients with SLE.…
Abstract Number: 0807 • ACR Convergence 2025
Deciphering Synovitis in Systemic Sclerosis
Celina Geiss¹, Miranda Houtman¹, Camino Calvo Cebrian¹, Raphael Micheroli², Melpomeni Toitou¹, Yannis Djeffal³, Alexandra Khmelevskaya¹, Mojca Frank-Bertoncelj¹, Sam Edalat¹, Thomas Rauer⁴, Kristina Bürki⁵, Chantal Pauli⁶, Michael Bonelli⁷, Thomas Karonitsch⁸, Oliver Distler⁹, Caroline Ospelt¹ and Muriel Elhai¹⁰, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³INSERM, IMRB, Université Paris Est Créteil, Paris, France, ⁴³Department of Traumatology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶Institute for Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Zurich, Switzerland, ⁷Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Wien, Austria, ⁸Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁰University Hospital zurich, Zürich, Switzerland
Background/Purpose: Synovitis is a common manifestation of systemic sclerosis (SSc), driving disability and predicting disease progression and mortality. Current immunosuppressive strategies, largely extrapolated from rheumatoid…
Abstract Number: 1852 • ACR Convergence 2025
Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort
Victoria Werth¹, Jun Kang², Lais Lopes Almeida Gomes³, Christopher Richardson⁴, Benjamin Chong⁵, J. Michelle Kahlenberg⁶, Joel Guthridge⁷, Wade DeJager⁸, Susan Macwana⁷, Caleb Marlin⁷, Judith James⁷, Rachael Bogle⁹, Alex Tsoi⁹ and Johann Gudjonsson⁶, ¹University of Pennsylvania, Wynnewood, PA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Rochester Medical Center, Rochester, NY, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Michigan, Ann Arbor, MI, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Oklahoma Medical Research Foundation, Oklahoma City, ⁹University of Michigan, Holland, OH
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease associated with systemic lupus erythematosus (SLE) and characterized by a prominent type I interferon…
Abstract Number: 1191 • ACR Convergence 2025
Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis
Alfredo Guzman, Elizabeth Bagley, Rita Spathis, Madison King, Kanneboyina Nagaraju and Melissa Morales, Binghamton University, Johnson City, NY
Background/Purpose: Dysregulation of the ER stress and interferon (IFN) pathways play a major role in the pathophysiology of autoimmune myositis. Upregulation of ER stress markers…
Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Eric Morand¹, Victoria Werth², Richard Furie³, Sanjeev Roy⁴, Ruth Fernandez Ruiz⁵, Summer Goodson⁶, Hans Gühring⁷, Flavie Moreau⁶ and David Pearson⁸, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, ⁵EMD Serono, Billerica, PA, ⁶EMD Serono, Billerica, MA, ⁷The healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…
Abstract Number: 1826 • ACR Convergence 2025
Single Nuclei Multiome of JDM Muscle Biopsies Reveals Novel Upregulation of Inflammatory and Vascular Pathways
Shannon O'Connor, Casey Swoboda, Matthew Weirauch, Alexander Zygmunt, Douglas Millay and Leah Kottyan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is a multisystem vasculopathy and inflammatory myopathy characterized by proximal muscle weakness, distinct rash, and risk of long-term complications such as…
Abstract Number: 1185 • ACR Convergence 2025
Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15
Stéphane Mitrovic¹, Athénaïs Boucly², Maryvonnick Carmagnat³, Laurent Savale², Xavier Jaïs², Jean-luc Taupin³, Estibaliz Lazaro⁴, Emilie Berthoux⁵, nicolas schleinitz⁶, Maria-Rosa Ghigna⁷, kedra joanna¹, Xavier Mariette⁸, Céline Roussin⁹, Pierre Antoine Juge¹⁰, Marc Humbert², Olivier Sitbon², David Montani² and Bruno Fautrel¹¹, ¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²Kremlin Bicêtre Hospital, Pulmonology Department, Paris Saclay University, APHP, Le Kremlin Bicêtre, France, ³Saint Louis Hospital, Immunology laboratory, APHP, Paris, France, ⁴Internal Medicine Department, CHU Bordeaux, Bordeaux, France, ⁵Saint Joseph Sain Luc Hospital, Internal Medicine Department, Lyon, Lyon, France, ⁶Aix Marseille university, AP-HM, Marseille, France, ⁷Marie Lannelongue Hospital, Anatomopathology department, Le Plessis-Robinson, France, ⁸Université Paris-Saclay, Le Kremlin Bicetre, France, ⁹Centre Hospitalier Ouest Réunion, Saint Paul, France, ¹⁰Hopital Bichat, APHP, Paris, France, ¹¹Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Inflammatory lung disease (ILD) in Still’s disease (SD) has recently been described. Pulmonary arterial hypertension (PAH), a rare subtype of pulmonary hypertension (PH), is…
Abstract Number: 0775 • ACR Convergence 2025
Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression
Anastasiia Phothisane¹, Tulsi Joishy², Carolina Ramirez-Becerra¹, Zuofei Wang², Qiong Wu³, Jennifer Seifert⁴, Marie Feser⁵, Jill Norris⁶, Kristen Demoruelle⁷, LauraKay Moss⁵, Kevin Deane⁸, V. Michael Holers⁹ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of Virginia, Charlottesville, VA, ⁴University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Colorado School of Public Health, Denver, CO, ⁷University of Colorado Anschutz Medical Campus, Golden, CO, ⁸University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁹University of Colorado Anschutz Medical Campus, Aurora
Background/Purpose: Microbial small RNAs (sRNAs) can regulate human genes, often with anti-inflammatory effects. We previously showed that an increased plasma concentration of a tRNA-derived RNA…
Abstract Number: 1777 • ACR Convergence 2025
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
Touraj Khosravi¹, Ahmed Eldaboush², Darae Kang³ and Victoria Werth², ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Potomac, MD
Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
Abstract Number: 0951 • ACR Convergence 2025
Epidermal IFNκ Increases Circulating and Cutaneous Monocytes in a C57/Bl6 Overexpression Mouse Model
Patrick O'Brien, Benjamin Klein, Deborah Colesa and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Lupus is a heterogeneous inflammatory autoimmune disease affecting a variety of organs, including skin manifestations such as photosensitivity and cutaneous lesions. The skin of…
Abstract Number: 0518 • ACR Convergence 2025
Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
Santos Castañeda¹, Alejandra Ramos-Manzano², Ines Sanchez-Abad³, Miren Uriarte-Ecenarro⁴, M. Paula Alvarez-Hernandez⁴, Esther San-Antonio⁴, Esther Vicente-Rabaneda⁵ and Ana Urzainqui⁴, ¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ²Hospital Unversitario de la Princesa, Madrid, Madrid, Spain, ³Hospitla de la Princesa, Madrid, Spain, ⁴Hospital de la Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease characterized by lymphocytic infiltration of exocrine glands and systemic manifestations including cutaneous and renal involvement. Phagocytes--monocytes,…
Abstract Number: 1775 • ACR Convergence 2025
Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM
pradeep sosigowda¹, Phani Kumar D¹, Megha Uppin¹ and Liza rajasekhar², ¹NIMS, Hyderabad, Telangana, India, ²Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases primarily affecting skeletal muscle, with potential involvement of other organs. They are classified…
Abstract Number: 0943 • ACR Convergence 2025
Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
Haylee Cosgrove¹, Xiaoyan Gong¹, Aidan Matunis¹ and Jeremy Tilstra², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The pathogenesis of systemic lupus erythematosus (SLE) is thought to be strongly influenced by the interferon (IFN) signaling pathway, particularly type I IFNs (IFNα/β).…
Abstract Number: 0508 • ACR Convergence 2025
Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
Clementine Pouenat¹, Marine Vierling², Chiara Meier³, Ludivine Robin⁴, Philippe Kolb⁵, Hartmut Hengel⁶, Gaetane Nocturne⁷, Divi Cornec⁸, Valerie Devauchelle⁹, Véronique Le Guern¹⁰, Claire larroche¹¹, Damien Sène¹², Marion Couderc¹³, Eric HACHULLA¹⁴, Philippe Dieude¹⁵, Olivier Vittecoq¹⁶, Jacques Morel¹⁷, Nicolas Meyer¹⁸, Raphaele Seror¹⁹, Reinhard Voll²⁰, Pierre-Marie Duret²¹, Laurent Miguet²², Xavier Mariette²³ and Jacques-eric GOTTENBERG²⁴, ¹IBMC, UPR ³⁵⁷², STRASBOURG, France, ²Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France,, Strasbourg, Alsace, France, ³Strasbourg University Hospital, Department ofRheumatology, STRASBOURG, France, ⁴Strasbourg University Hospital, Department of pathology, ⁴CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France Strasbourg, France;, Strasbourg, Alsace, France, ⁵INSTITUTE OF VIROLOGY Medical Center, Freiburg, Freiburg, Germany, ⁶INSTITUTE OF VIROLOGY University Hospital Freiburg, FREIBURG, Germany, ⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ⁸LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁹UBO, Brest, France, ¹⁰Cochin hospital, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne APHP, Bobigny, Paris, Ile-de-France, France, ¹²Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹³Service de Rhumatologie CHU Clermont-Ferrand, Clermont-Ferrand, ¹⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, ¹⁵Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ¹⁶Service de Rhumatologie & CIC-CRB ¹⁴⁰⁴, CHU de Rouen, Université de Rouen, Rouen, Rouen, France, ¹⁷CHU and University of Montpellier, Montpellier, France, ¹⁸Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France, Strasbourg, Alsace, France, ¹⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²⁰University Medical Center Freiburg, Freiburg, Germany, ²¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²²Haemtology, Strasbourg University Hospital, IBMC UPR ³⁵⁷², Strasbourg, France, ²³Université Paris-Saclay, Le Kremlin Bicetre, France, ²⁴Hautepierre Hospital, STRASBOURG, Alsace, France
Background/Purpose: Fc‐gamma receptor (FcγR) activation by soluble IgG immune complexes (sICs) is considered to play a pivotal pathogenic role in B-cell-mediated autoimmune diseases, such as…

1
2
3
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].